Schroer John R. sold $87K of ALMS

Schroer John R. (Chief Financial Officer) sold 3,282 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Schroer John R.
Published Aug 5, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
medium confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale of 3,282 shares at $26.37, totaling about $86.5K, with holdings after the trade of 24,718 shares.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks any fundamental catalyst or magnitude that would typically drive repricing.

03

What to watch

The article does not state motivations, tax events, or whether other insiders are buying/selling, so the signal quality is limited.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralMedium confidence
Context

ALMS CFO John R. Schroer filed a Form 4 selling 3,282 shares at $26.37 on 2026-08-03, disclosing direct insider selling activity.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4, but the article provides only a single open-market sale and no accompanying company-specific catalyst, guidance, or legal/regulatory development.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for liquidity or diversification; the absence of a 10b5-1 plan does not necessarily imply negative information.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed via SEC Form 4.

  • John R. Schroer

    Chief Financial Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.